PitSTOP
Start date:August 2017 End date:
August 2018 Co-ordinated by:
Dr John Emelifeonwu and the EMERGE Team, RIE Main trial site:
RIE
Primary Objective
To determine the prevalence of anterior pituitary gland dysfunction in traumatic brain injury in Scotland.
Secondary Objectives
To determine whether clinical and radiologically parameters available on presentation can predict likelihood of developing PTPD in patients with TBI.
To determine the optimal timing after TBI for blood tests to diagnose PTPD
To determine whether PTPD effects functional recovery as determined by the extended Glasgow Outcome Score (eGOS)
Chief Investigator
Dr John Emelifeonwu
Surgical Trainee, Clinical Neurosciences
Research Team
Mia Paderanga
Senior Research Nurse
Julia Grahamslaw
Lead Research Nurse
More EMERGE Trials
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.
TARGET-CTCA Trial
Assisting in identifying patients with Humeral shaft fractures in the ED by screening.
Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.
HU-FIX Trial
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.